GH Research (GHRS) Stock Price, Quote, News & History | Benzinga

GH Research PLC (GHRS) Stock Price, Quote, News & History

GHRSNASDAQ

Trade with Public

Trade with Public

$28.10

-2.14-7.08%

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, before the market open

OverviewNews Earnings Forecast Price Targets Financials Sentiment Compare Options Stock Report

Key Statistics

Open

$30.30

Close

-

Volume / Avg.

284.00K / 298.21K

Day Range

$28.17 - $30.31

52 Wk Range

11.80 - 31.44

Market Cap

$1.93B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

51

Short Interest

9.41%

Days to Cover

7.3

Recent GH Research PLC News

Why Is GH Research Stock Trading Higher on Thursday?

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.

Vandana Singh

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets, stock fell 3.4%. CEO noted progress in GH001 program.

Avi Kapoor

Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday

Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.

Avi Kapoor

Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?

Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews

Namrata Sen

Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $17 billion. Shares jump 20.2% to $493.01.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-51.70M

Investing Cash Flow (TTM)

33.60M

Financing Cash Flow (TTM)

111.74M

Free Cash Flow (TTM)

-51.84M

Capital Expenditure (TTM)

-138.00K

Net Change in Cash (TTM)

93.64M

Analyst Trends and Forecast

2

Mar

2

May

1

Jul

3

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.71B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

5.77

Earnings Yield % (TTM)

-3.27%

Earnings Yield % (FWD)

-3.77%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.24

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$275.00K

Total Cash

$345.05M

Debt to Equity

0.00

Issuance of Debt (TTM)

-$275.00K

Repayment of Debt (TTM)

-$275.00K

Key Statistics

Open

$30.30

Close

-

Volume / Avg.

284.00K / 298.21K

Day Range

$28.17 - $30.31

52 Wk Range

11.80 - 31.44

Market Cap

$1.93B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

51

Short Interest

9.41%

Days to Cover

7.3

About

Sector

Health Care

Industry

Pharmaceuticals

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies f...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy GH Research (GHRS) stock?

A

You can purchase shares of GH Research (NASDAQ:GHRS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are GH Research (GHRS) competitors?

A

Other companies in GH Research’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for GH Research (GHRS) stock?

A

GH Research has a consensus price target of $40.50.

Q

What is the current price for GH Research (GHRS)?

A

The stock price for GH Research (NASDAQ: GHRS) is $28.1 last updated August 13, 2026 at 3:46 PM EDT.

Q

Does GH Research (GHRS) pay a dividend?

A

There are no upcoming dividends for GH Research.

Q

When is GH Research (NASDAQ:GHRS) reporting earnings?

A

GH Research does not have any upcoming earnings scheduled.

Q

Is GH Research (GHRS) going to split?

A

There is no upcoming split for GH Research.

Q

What sector and industry does GH Research (GHRS) operate in?

A

GH Research is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.